Ateneo - UPO

The course will provide the tools to understand the management of the complexities related to hematopoietic stem cell transplantation, CAR-T cell therapies, to the new biological drugs precision medicine and to clinical trials. Some issues related to bioethical implications of clinical research will be discussed

Teaching materials used during lessons (slides, etc) will be pivotal for exam preparation

As an additional learning tool (consultation only)

Giuliani N, Olivieri A. EMATOLOGIA. Idelson-Gnocchi, 2020. The textbook does not surrogate for slides and materials used during the lesson

The educational objective of the course is to enable students to know, interpret and analyse the main haematological issues relevant to the course in a critical manner, as required by Dublin descriptor 3.

Basic knowledge of blood disorders

taught (frontal) classes with slide presentations

Students with physical disabilities, Learning Disabilities or Special Education Needs can request
specific services and tools via the Staff Sviluppo e Coordinamento Carriere e Servizi alle Studentesse
e agli Studenti, consulting the University webpage: https://www.uniupo.it/en/services/servicesstudents-physical-or-learning-disabilities
Students with disabilities, learning disabilities or special education needs, once they have contacted
the University Staff, can refer to the tutor in charge of the course to define the examination
modalities, concerning academic aspects.

The exam of Blood Diseases will be based on 12 MCQs (4 possible answers, of which only 1 is correct), on the topics taught during classes

A. Transplant of hematopoietuc stem cells and CAR-T therapies: autologous transplant; allogeneic transplant; transplant and CAR-T complications complications; Graft versus host diseases (GVHD); CRS and neurotoxicity complexity of transplant procedures

B. Precision Medicine and new drugs in hematoncology: monoclonal antibodies; "small molecules" for target therapies

C. Clinical trials in hematocology: phase I, phase II, phase III; the concept of "benefit sharing" in hematological scientific research; other bioethical issues in clinical research

At the end of the course, students will be able to critically analyse: i) the strategy of transplant procedures of hematopoietic stem cells and CAR-T therapies; ii) the complexity of new drugs in hematoncology; iii) the methodology and problematics of clinical trials in hematoncology